Theratechnologies Inc T.TH

THTX start commenting

[scarlet1967]

 

 

 

 

 

It seems that they have filled that position as the posting is removed from LinkedIn and their website, also in January this year they hired a legal/medical advisor! As for preclinical projects I believe there are some ongoing studies in collaboration with UQAM, CQDM and Canadian cancer society which was funded in July 2022.

Is THTX and their partners all looking for people for the preclinical studies? Is the last global clinical… posting/ recruit was entirely/only for preclinical studies?

I don’t believe so because most if not all their preclinical studies are run by UQAM who is also looking for research assistant under supervision of very well merited researchers “ principal investigator, senior research assistant”. Why adding research folks to the payroll for a cash strapped company which is planning/prioritizing  profitability? 

Again THTX what are you up to? Let us know in timely manner as excising shareholders won’t like to be kept in the dark for too long especially after all these turns and twists in your R&D projects and current valuation which is a nightmare.

Any potential future retail investors will not get involved unless there is clear picture of what the company is up to even at these low prices. Decent frequent information sharing is a must to do for this ignored company despite $80 million sales and anticipated double digits sale growth. Are the R&D projects and all the current employees with expertise in hepatology/oncology a value lost or value added assets? What’s the process and why? What’s the progress? Bear or bull market you will be valued based on commercial success and or the value of the R&D. As per commercial success the numbers will say it all but the R&D projects need rationalized and convincing explanations of theirs achievable potentials, scientifically and financially. You let the market know and let it decide the probability of success stay quite the focus will be on the probability of failure. 

 

https://www.theratech.com/news-releases/news-release-details/cqdm-quebec-breast-cancer-foundation-and-theratechnologies-fund

 

Theratechnologies Inc. hiring Chef de l’assurance de la qualit clinique mondiale | Manager, Global Clinical Quality Assurance in Montreal, Quebec, Canada | LinkedIn

Theratechnologies Inc. hiring Chef de l’assurance de la qualit clinique mondiale | Manager, Global Clinical Quality Assurance in Montreal, Quebec, Canada | LinkedIn

https://www.linkedin.com/in/genevi%C3%A8ve-lefebvre-aa0009116

 

“Legal Advisor, Medical Affairs

 Theratechnologies Inc.

 Jan 2023 - Present • 2 months

 Montreal, Quebec, Canada Assist the legal affairs team in the review and drafting of commercial and medical contracts.”

 

Universit du Qubec Montral hiring Assitant / Associ de recherche in Montreal, Quebec, Canada

Universit du Qubec Montral hiring Assitant / Associ de recherche in Montreal, Quebec, Canada

 

“Our molecular oncology research laboratory is interested in the development and characterization of a new therapeutic approach against cancer.

 This project is carried out in collaboration with Theratechnologies Inc., a biopharmaceutical company specializing in the marketing and development of drugs that meet unmet needs and is jointly funded by the Consortium Qubcois pour la Dcouverte du Mdicament (CQDM) and the Canadian Cancer Society  .

 Job Description :

 The Research Assistant/Associate will work under the supervision of the Principal Investigator or a Senior Research Associate.  The candidate will perform various scientific and administrative tasks.

 Responsibilities:

 -Have excellent skills in cell culture, microscopy, immunofluorescence, cell and molecular biology (RNA and protein extraction, RT-PCR,

 qPCR, Western-type immunoblotting), cytotoxicity and cell proliferation assays, flow cytometry, manipulation of radioisotopes;

 -Have proven experience in pharmacology and development of ligand binding and internalization assays;

 -Compile, analyze and interpret its results;

 -Maintain an up-to-date laboratory notebook and follow standard operating procedures;

 -Participate in the tasks necessary for the proper functioning of the laboratory.

 

Requirements:

 -University degree (M.Sc., Ph.D.) in biomedical sciences, cell biology, biology, biochemistry, pharmacology or in a related field;

 -Experience in a pharmaceutical environment would be an asset;

 - Ability to organize and document (literature review)

 -Knowledge of Word, Excel, Power Point, and

 GraphPad Prism.

 Personal qualities:

 -Positive, enthusiastic personality,

 

Submission of applications:

 Interested candidates should send their CV, a brief cover letter, and the contact details of

 2-3 people referred by email to Borhane

 Annabi, principal researcher ([e-mail]).

 PS: We thank all applicants for their interest.  Only the people selected for an interview will be contacted.  UQAM subscribes to employment equity.”

 

[realitycheck4u]

This post has been removed in accordance with Community Policy

[scarlet1967]

Because his suggestion starting from scratch manufacturing a new PDC with more stable cleavable linker and more potent cytokines doesn't solve the issue and it's not feasible. They don't have resources to start over and if so the sort1 technology is based on over expressed sortilin and transponders responsible for the efflux on cancer cells versus healthy cells which means more

[jfm1330]

You just laid out again the company's story that failed as it is, up to now. At this point, again, we don't care about their preclinical results on mice xenografted with pure cancer cell lines. Real advanced cancers on real human patients are much more complex and what really matters is the results they got on these patients and what they learned out of them. If the data they collected on

[SPCEO1]

That was a good post JFM - thanks! If the truck is OK and they do not come up with a partner that throws off serious cash to them in NASH or a partner for Sort1+, then they really don't have the money to pursue a new attempt at TH-1902. Cost cutting/sales increases are not going to free up the needed funds either. So, THTX has a number of problem to solve but it is not impossible that they can

[jfm1330]

The key at this point is the data they have on humans and what it shows. Again, if the data allows to confirm a proof of concept, i.e.: the truck being able to enter the delivry point, then it would be much easier to attract a partner, and ideally a partner with the knowledge and technical assets to fix the problems, new linker and/or new cytotoxic agent. And, with a great partner that has the

[qwerty22]

You're doing hindsight science. You're assuming they knew there was a leaky tank and they should've done something about it. Well they didn't know. From what we know they had a pretty good run in preclinical that generally said the truck is running fine. When they published the preclinical paper I thought they'd done a pretty strong job of dissecting each step in the process of

[Wino115]

This is the month they'll get their first chance to talk. The path to Ebitda breakeven and new revenue estimates will be important - especially their new market size numbers and what they are doing to penetrate it. Anything to bolster confidence their $90-95mil revenue target is realistic would be positive and provide some reassurance that maybe $100mil+ is doable the following year, which

[Trogarzon]

They keep hiring people without explaining anything while they say they will cut expenses out of the other corner of their mouth.  It's confusing and it sends a conflictual message to a market that they keep ignoring with their typical opacity and carelesness. They better asses the urgent short term problem they face with their shareholders if this turd stays in the stock sewer until may

[palinc2000]

Where did you see that they would cut expenses? All I read is that they are guiding for positive Ebitda in 2023 and that they will be taking that into account in deciding how fast they proceed  and how much they spend on the development of TH 1902  Massive cuts are not what they guided! The way to positive Ebitda is thru sales growth in the legacy drugs and possibly thru acquisition

[Wino115]

The financial strategy has to be addressed in more detail in a few weeks to really know. They need a combo of revenue growth and cost control to add up to $30mil or so needed at the EBITDA level. Reveneus will add $10-15mil based on their estimate (I'd use the low end to be safe). We also don't know if they've hired those slots or just taken the search down, or filled internally.  

[palinc2000]

My hope is that they dont  go into lock down mode ......they ran into a road block by improvising into something in which they were flying blind due to lack of knowledge lack of experience lack of structure and without the financial strentght sufficient to really support such a risky venture,,,If they can get a pharma to compensate for  the 15 million $  ( my estimate) spent so far